{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:55Z","timestamp":1787017075550,"version":"build-2736575974"},"reference-count":31,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,22]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The cardiotoxicity of immune checkpoint inhibitors (ICIs) has garnered significant clinical attention due to its high mortality rate. However, limited clinical research and inconsistent results have hindered a comprehensive understanding of this issue. This study seeks to elucidate gender and age differences in cardiac-related adverse reactions, aiming to offer scientific evidence to inform clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective pharmacovigilance study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Based on the reports of ICIs in the FDA Adverse Event Reporting System database from 2003\u20132023, we conducted a disproportionality analysis to identify cardiac immune-related adverse events (irAEs) and explored the correlation of age and gender with these adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The main cardiac irAEs were defined by four preferred terms: myocarditis, atrial fibrillation, cardiac failure and pericardial effusion. Both the proportional reporting ratio (PRR) and reporting odds ratio (ROR) are frequency methods. Data mining was performed using the PRR method, which assesses the relative risk of adverse drug reactions by comparing the frequency of reports associating a specific drug with a particular adverse reaction to the frequency of reports linking any drug to the same reaction. A higher PRR indicates a more robust adverse event signal, suggesting a stronger statistical association between the drug of interest and the target adverse event. In the research process, we primarily used the ROR and PRR from disproportionality analysis to screen for cardiac irAEs, while also elucidating the correlation between these reactions and factors such as age and gender.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2033 adverse events were retrieved, and myocarditis was the most common cardiac irAEs. Gender disparities exist in the incidence of various adverse reactions to the same medication. Female patients need to be particularly vigilant for cardiac adverse events when taking atezolizumab, and male patients should be especially cautious for cardiac adverse events when using ipilimumab. Furthermore, ipilimumab produced a positive signal for pericardial effusion in the elderly group but not in the younger group, suggesting that elderly patients may be more susceptible to adverse reactions. Therefore, increased vigilance and careful monitoring are warranted during clinical administration of this medication to elderly patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study highlights the gender and age differences in cardiac adverse events with ICIs, providing valuable insights for clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090087","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:30:18Z","timestamp":1749713418000},"page":"e090087","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-7251","authenticated-orcid":false,"given":"Wenya","family":"Shan","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Zhejiang University of Technology, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2025121404305998000_15.6.e090087.1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025121404305998000_15.6.e090087.2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune Checkpoint Inhibitor-Associated Pericarditis","volume":"14","author":"Altan","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025121404305998000_15.6.e090087.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30673-9"},{"key":"2025121404305998000_15.6.e090087.4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025121404305998000_15.6.e090087.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025121404305998000_15.6.e090087.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025121404305998000_15.6.e090087.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa051","article-title":"Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent\/metastatic thymic carcinoma patient: a case report","volume":"4","author":"Szuchan","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"2025121404305998000_15.6.e090087.8","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.18632\/oncotarget.13315","article-title":"Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"2025121404305998000_15.6.e090087.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.09.002"},{"key":"2025121404305998000_15.6.e090087.10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0047"},{"key":"2025121404305998000_15.6.e090087.11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025121404305998000_15.6.e090087.12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001901","article-title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","volume":"9","author":"Marron","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025121404305998000_15.6.e090087.13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-022-02568-y","article-title":"Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States","volume":"42","author":"Yang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"2025121404305998000_15.6.e090087.14","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121404305998000_15.6.e090087.15","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2289"},{"key":"2025121404305998000_15.6.e090087.16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.616505","article-title":"Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025121404305998000_15.6.e090087.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4"},{"key":"2025121404305998000_15.6.e090087.18","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920"},{"key":"2025121404305998000_15.6.e090087.19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025121404305998000_15.6.e090087.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034497"},{"key":"2025121404305998000_15.6.e090087.21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11523-021-00865-8","article-title":"Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System","volume":"17","author":"Sisi","year":"2022","journal-title":"Targ Oncol"},{"key":"2025121404305998000_15.6.e090087.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2018","journal-title":"PLoS One"},{"key":"2025121404305998000_15.6.e090087.23","doi-asserted-by":"crossref","DOI":"10.1038\/srep24955","article-title":"Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events","volume":"6","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"key":"2025121404305998000_15.6.e090087.24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025121404305998000_15.6.e090087.25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijcard.2021.09.041","article-title":"Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies","volume":"344","author":"Sun","year":"2021","journal-title":"Int J Cardiol"},{"key":"2025121404305998000_15.6.e090087.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdtm.2019.02.004"},{"key":"2025121404305998000_15.6.e090087.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571"},{"key":"2025121404305998000_15.6.e090087.28","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jfma.2019.07.025","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"2025121404305998000_15.6.e090087.29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.currproblcancer.2018.07.002","article-title":"Cardiotoxicities associated with immune checkpoint inhibitors","volume":"42","author":"Yang","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"2025121404305998000_15.6.e090087.30","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2025121404305998000_15.6.e090087.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.05.006"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:31:10Z","timestamp":1765715470000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,12]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-090087"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090087","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}